Need Help?

Mechanism and targeted therapy of Vemurafenib-Resistant Hairy-Cell Leukemia

The discovery of the BRAF V600E mutation in almost all cases of hairy-cell leukemia has led to the widespread adoption of the BRAF inhibitor vemurafenib for treatment of chemotherapy-resistant cases. Impressive responses are reported; however, acquired resistance is common. Whilst diverse mechanisms of vemurafenib resistance have been elucidated in melanoma, the basis of resistance in HCL is unclear. Here we apply whole genome and deep targeted sequencing to investigate resistance mechanisms and potential therapeutic strategies in a patient with aquired resistance to vemurafenib.

Request Access

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001002261 Cancer Genomics

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Quality Report
Located in
EGAF00001748881 cram 515.6 MB Report
EGAF00001748882 cram 475.3 MB Report
EGAF00001748883 cram 508.0 MB Report
EGAF00001748884 cram 532.7 MB Report
EGAF00001748885 cram 488.4 MB Report
EGAF00001748886 cram 512.7 MB Report
EGAF00001748887 cram 489.9 MB Report
EGAF00001748888 cram 607.9 MB Report
EGAF00001748889 cram 620.3 MB Report
EGAF00001748890 cram 625.2 MB Report
EGAF00001748891 cram 665.5 MB Report
EGAF00001748892 cram 593.7 MB Report
EGAF00001748893 cram 590.3 MB Report
EGAF00001748894 cram 598.7 MB Report
EGAF00001748895 cram 554.4 MB Report
EGAF00001748896 cram 513.8 MB Report
EGAF00001748897 cram 473.7 MB Report
EGAF00001748898 cram 506.3 MB Report
EGAF00001748899 cram 530.7 MB Report
EGAF00001748900 cram 486.5 MB Report
EGAF00001748901 cram 511.0 MB Report
EGAF00001748902 cram 488.3 MB Report
EGAF00001748903 cram 605.7 MB Report
EGAF00001748904 cram 618.6 MB Report
EGAF00001748905 cram 623.0 MB Report
EGAF00001748906 cram 662.7 MB Report
EGAF00001748907 cram 591.2 MB Report
EGAF00001748908 cram 587.8 MB Report
EGAF00001748909 cram 596.2 MB Report
EGAF00001748910 cram 552.5 MB Report
EGAF00001748911 cram 512.7 MB Report
EGAF00001748912 cram 473.2 MB Report
EGAF00001748913 cram 505.4 MB Report
EGAF00001748914 cram 530.2 MB Report
EGAF00001748915 cram 486.0 MB Report
EGAF00001748916 cram 510.1 MB Report
EGAF00001748917 cram 487.5 MB Report
EGAF00001748918 cram 604.6 MB Report
EGAF00001748919 cram 617.7 MB Report
EGAF00001748920 cram 622.3 MB Report
EGAF00001748921 cram 661.9 MB Report
EGAF00001748922 cram 590.3 MB Report
EGAF00001748923 cram 587.1 MB Report
EGAF00001748924 cram 595.2 MB Report
EGAF00001748925 cram 551.6 MB Report
EGAF00001748926 cram 512.0 MB Report
EGAF00001748927 cram 472.6 MB Report
EGAF00001748928 cram 504.9 MB Report
EGAF00001748929 cram 529.2 MB Report
EGAF00001748930 cram 485.4 MB Report
EGAF00001748931 cram 509.6 MB Report
EGAF00001748932 cram 486.6 MB Report
EGAF00001748933 cram 604.3 MB Report
EGAF00001748934 cram 617.1 MB Report
EGAF00001748935 cram 621.6 MB Report
EGAF00001748936 cram 661.0 MB Report
EGAF00001748937 cram 590.0 MB Report
EGAF00001748938 cram 586.7 MB Report
EGAF00001748939 cram 595.0 MB Report
EGAF00001748940 cram 551.3 MB Report
EGAF00001748941 cram 511.4 MB Report
EGAF00001748942 cram 471.5 MB Report
EGAF00001748943 cram 503.8 MB Report
EGAF00001748944 cram 528.3 MB Report
EGAF00001748945 cram 484.2 MB Report
EGAF00001748946 cram 508.7 MB Report
EGAF00001748947 cram 485.8 MB Report
EGAF00001748948 cram 602.9 MB Report
EGAF00001748949 cram 615.6 MB Report
EGAF00001748950 cram 620.0 MB Report
EGAF00001748951 cram 659.4 MB Report
EGAF00001748952 cram 588.6 MB Report
EGAF00001748953 cram 585.1 MB Report
EGAF00001748954 cram 593.3 MB Report
EGAF00001748955 cram 549.6 MB Report
75 Files (41.7 GB)